This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Reconstitution of HIV-specific Immunity Against HIV

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Linghua LI, Guangzhou 8th People's Hospital
Sponsor:
Collaborator:
Sun Yat-sen University
Information provided by (Responsible Party):
Linghua LI, Guangzhou 8th People's Hospital
ClinicalTrials.gov Identifier:
NCT02563509
First received: September 13, 2015
Last updated: May 21, 2017
Last verified: May 2017
  Purpose
Research Goal: To reconstitute the anti-HIV specific immunity system of the AIDS patients, so the viruses could not massively replicate when HAART was discontinued, then make HIV functional cure possible.

Condition Intervention Phase
HIV Biological: HIV-specific CD8 cells Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Reconstitution of HIV-specific Immunity Against HIV

Resource links provided by NLM:


Further study details as provided by Linghua LI, Guangzhou 8th People's Hospital:

Primary Outcome Measures:
  • The number and function of HIV-specific CD8 cells in patients with HIV [ Time Frame: 6 Months ]
    The change of differentiation, proliferation, apoptosis, phenotype, etal.


Secondary Outcome Measures:
  • All adverse events [ Time Frame: 6 Months ]
    Chills, Fever, Headache, Nausea, Vomiting, Cough, Skin rashes, Anaphylactic shock, Etal.


Estimated Enrollment: 40
Study Start Date: January 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HIV-specific CD8 cells
Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.
Biological: HIV-specific CD8 cells
Based on HAART, receive HIV-specific CD8 cells transfuion.
No Intervention: Regualar therapy
Only receiving Highly active anti-retroviral therapy(HAART).

Detailed Description:
The research aims at establishing a new treatment strategies of HIV. It will significantly improve the clinical therapy effects and effectively reduce the morbidity and mortality by reconstituting the immune systems of HIV infected patients and combining multiple therapy strategies. Therefore, the research could develop an cloning amplification system of immunocytes in vitro, and improve the antiviral immune system severely damaged before by transfusing the clone cells modified by specific HIV antigen. So HIV infected patients could discontinue the traditional anti-viral drug, but not develop opportunistic infections,which could obviously increase the life qualities of these patients.
  Eligibility

Ages Eligible for Study:   16 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. HIV infection confirmed
  2. Receiving HAART more than 6 months
  3. HIV viral-load < 50 copies/ml
  4. Without serious damage of liver and kidney
  5. The subject volunteered to the research and sign the informed consent

Exclusion Criteria:

  1. With serious opportunistic infections
  2. With serious chronic disease such like diabetes, the mental illness,et al
  3. History of suffering from pancreatitis during HAART.
  4. Pregnant and breast-fed.
  5. With poor adherence
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02563509

Contacts
Contact: LingHua LI, doctor 13725297174 llheliza@126.com

Locations
China, Guangdong
Guangzhou 8th People's Hospital Recruiting
Guangzhou, Guangdong, China, 510060
Contact: Linghua LI, doctor    13725297174    llheliza@126.com   
Sponsors and Collaborators
Guangzhou 8th People's Hospital
Sun Yat-sen University
Investigators
Principal Investigator: Hui Zhang, doctor Sun Yat-sen University
  More Information

Publications:

Responsible Party: Linghua LI, Chief physician, Guangzhou 8th People's Hospital
ClinicalTrials.gov Identifier: NCT02563509     History of Changes
Other Study ID Numbers: 2013ZX10001004
Study First Received: September 13, 2015
Last Updated: May 21, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Linghua LI, Guangzhou 8th People's Hospital:
HIV
cellular immunity therapy
functional cure

ClinicalTrials.gov processed this record on June 23, 2017